|
January 23, 2008 Genetic and Metabolic Screening - New Provisions
REGULATORY CHANGES. On September 14, 2007, the IDPH posted adopted changes to the Newborn Metabolic Screening and Treatment Code that include adding cystic fibrosis (CF) to the list of diseases for which infant screening is required in Illinois. A phase-in project requiring CF screening of babies born at certain Illinois hospitals will begin this month. At the end of that phase-in project, on March 3, 2008, all specimens submitted to the IDPH Newborn Screening Laboratory will be tested for CF. The Department increased the fee for the analysis of specimens. In addition, Section 661.20 of the Code, "Collection of Blood and Submission of Specimens" was amended to require: Unchanged Blood Specimen Provisions. The Code continues to require, for infants not born in or admitted to a hospital during the neonatal period, that a blood specimen be collected as soon as possible, but no earlier than 24 hours after birth; and submission of specimens to the Department lab, within 24 hours of collection is highly recommended. The complete text of the revised section of the Code may be accessed by clicking here. LEGISLATIVE CHANGES. On November 5, 2007, Governor Blagojevich signed into law the Genetic and Metabolic Diseases Advisory Committee Act, Public Act 95-0695, effective immediately. This Act creates an advisory committee to advise the Department of Public Health regarding issues relevant to newborn screenings of metabolic diseases. The Act also amends the Phenylketonuria Testing Act by changing its name to the "Newborn Metabolic Screening Act" and providing for the conduct of new screenings, according to a specified timetable, for the Lysosomal Storage Disorders known as Krabbe, Pompe, Gaucher, Fabry, and Niemann-Pick. It is the goal of the legislation to have the expanded screening for these disorders begin within three years after the effective date of this Act (November 5, 2007). The Act authorizes the Department to implement an additional fee for the screening prior to beginning the testing in order to accumulate the resources for start-up and other costs related to screening and follow-up programs. The complete text of the Genetic and Metabolic Diseases Advisory Committee Act (P.A. 95-0695) may be accessed by clicking here. Staff Contact: Barb Haller at bhaller@ihastaff.org or 630.276.5474. | |||||
| Copyright © 2008 Illinois Hospital Association | |||||